You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 18, 2025

OFEV Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Ofev patents expire, and when can generic versions of Ofev launch?

Ofev is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and ninety-seven patent family members in fifty-three countries.

The generic ingredient in OFEV is nintedanib esylate. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the nintedanib esylate profile page.

DrugPatentWatch® Generic Entry Outlook for Ofev

Ofev was eligible for patent challenges on October 15, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 7, 2029. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (nintedanib esylate), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

< Available with Subscription >

  Try for Free

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for OFEV?
  • What are the global sales for OFEV?
  • What is Average Wholesale Price for OFEV?
Drug patent expirations by year for OFEV
Drug Prices for OFEV

See drug prices for OFEV

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for OFEV
Generic Entry Date for OFEV*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for OFEV
Drug ClassKinase Inhibitor
Mechanism of ActionProtein Kinase Inhibitors
Paragraph IV (Patent) Challenges for OFEV
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
OFEV Capsules nintedanib esylate 100 mg and 150 mg 205832 4 2018-10-15

US Patents and Regulatory Information for OFEV

OFEV is protected by four US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of OFEV is ⤷  Try for Free.

This potential generic entry date is based on patent 9,907,756.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim OFEV nintedanib esylate CAPSULE;ORAL 205832-001 Oct 15, 2014 RX Yes No 6,762,180*PED ⤷  Try for Free Y ⤷  Try for Free
Boehringer Ingelheim OFEV nintedanib esylate CAPSULE;ORAL 205832-002 Oct 15, 2014 RX Yes Yes 6,762,180*PED ⤷  Try for Free Y ⤷  Try for Free
Boehringer Ingelheim OFEV nintedanib esylate CAPSULE;ORAL 205832-001 Oct 15, 2014 RX Yes No 10,154,990*PED ⤷  Try for Free Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for OFEV

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim OFEV nintedanib esylate CAPSULE;ORAL 205832-001 Oct 15, 2014 7,119,093 ⤷  Try for Free
Boehringer Ingelheim OFEV nintedanib esylate CAPSULE;ORAL 205832-001 Oct 15, 2014 7,989,474 ⤷  Try for Free
Boehringer Ingelheim OFEV nintedanib esylate CAPSULE;ORAL 205832-002 Oct 15, 2014 7,989,474 ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for OFEV

When does loss-of-exclusivity occur for OFEV?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 2059
Patent: FORMA DE DOSIFICACION FARMACEUTICA EN CAPSULA QUE COMPRENDE UNA FORMULACION EN SUSPENSION DE UN DERIVADO DE INDOLINONA
Estimated Expiration: ⤷  Try for Free

Australia

Patent: 09254548
Patent: Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
Estimated Expiration: ⤷  Try for Free

Patent: 15227503
Patent: Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
Estimated Expiration: ⤷  Try for Free

Brazil

Patent: 0913434
Patent: forma de dosagem farmacêutica em cápsula compreendendo uma formulação de um derivado de indolinona em supensão
Estimated Expiration: ⤷  Try for Free

Canada

Patent: 26267
Patent: FORME POSOLOGIQUE PHARMACEUTIQUE EN CAPSULE COMPRENANT UNE FORMULATION EN SUSPENSION D'UN DERIVE D'INDOLINONE (CAPSULE PHARMACEUTICAL DOSAGE FORM COMPRISING A SUSPENSION FORMULATION OF AN INDOLINONE DERIVATIVE)
Estimated Expiration: ⤷  Try for Free

Chile

Patent: 10001279
Patent: Forma de dosificacion que comprende 3-z-[1-(4-(n-((4-metil-piperazin-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metileno]-6-metoxicarbonil-2-indolinona-monoetanosulfonato, un vehiculo lipidico, un espesante y un agente de deslizamiento/solubilizante, de grupos definidos.
Estimated Expiration: ⤷  Try for Free

China

Patent: 2056598
Patent: Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
Estimated Expiration: ⤷  Try for Free

Patent: 5193720
Patent: CAPSULE PHARMACEUTICAL DOSAGE FORM COMPRISING A SUSPENSION FORMULATION OF AN INDOLINONE DERIVATIVE
Estimated Expiration: ⤷  Try for Free

Colombia

Patent: 80467
Patent: FORMA DE DOSIFICACION FARMACEUTICA EN CAPSULA QUE COMPRENDE UNA FORMULACION EN SUSPENSION DE UN DERIVADO DE INDOLINONA
Estimated Expiration: ⤷  Try for Free

Croatia

Patent: 0180709
Estimated Expiration: ⤷  Try for Free

Cyprus

Patent: 20533
Estimated Expiration: ⤷  Try for Free

Denmark

Patent: 99987
Estimated Expiration: ⤷  Try for Free

Ecuador

Patent: 10010660
Patent: FORMA DE DOSIFICACIÓN FARMACÉUTICA EN CÁPSULA QUE COMPRENDE UNA FORMULACIÓN EN SUSPENCIÓN DE UN DERIVADO DE INDOLINONA
Estimated Expiration: ⤷  Try for Free

Eurasian Patent Organization

Patent: 9996
Patent: КАПСУЛЯРНАЯ ЛЕКАРСТВЕННАЯ ФОРМА, СОДЕРЖАЩАЯ СУСПЕНЗИОННУЮ КОМПОЗИЦИЮ ПРОИЗВОДНОГО ИНДОЛИНОНА (CAPSULE PHARMACEUTICAL DOSAGE FORM COMPRISING A SUSPENSION FORMULATION OF AN INDOLINONE DERIVATIVE)
Estimated Expiration: ⤷  Try for Free

Patent: 1001856
Patent: КАПСУЛЯРНАЯ ЛЕКАРСТВЕННАЯ ФОРМА, СОДЕРЖАЩАЯ СУСПЕНЗИОННУЮ КОМПОЗИЦИЮ ПРОИЗВОДНОГО ИНДОЛИНОНА
Estimated Expiration: ⤷  Try for Free

European Patent Office

Patent: 99987
Patent: FORME POSOLOGIQUE PHARMACEUTIQUE EN CAPSULE COMPRENANT UNE FORMULATION EN SUSPENSION D'UN DÉRIVÉ D'INDOLINONE (CAPSULE PHARMACEUTICAL DOSAGE FORM COMPRISING A SUSPENSION FORMULATION OF AN INDOLINONE DERIVATIVE)
Estimated Expiration: ⤷  Try for Free

Hungary

Patent: 39187
Estimated Expiration: ⤷  Try for Free

Israel

Patent: 8954
Patent: צורת מינון רוקחית שהינה קפסולה המכילה הרכב תרחיפי של נגזרת אינדולינון (Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative)
Estimated Expiration: ⤷  Try for Free

Japan

Patent: 61031
Estimated Expiration: ⤷  Try for Free

Patent: 05542
Estimated Expiration: ⤷  Try for Free

Patent: 11522812
Estimated Expiration: ⤷  Try for Free

Patent: 14208712
Patent: インドリノン誘導体の懸濁液製剤を含むカプセル医薬投薬形態 (CAPSULE PHARMACEUTICAL DOSAGE FORM COMPRISING SUSPENSION FORMULATION OF INDOLINONE DERIVATIVE)
Estimated Expiration: ⤷  Try for Free

Lithuania

Patent: 99987
Estimated Expiration: ⤷  Try for Free

Malaysia

Patent: 8930
Patent: CAPSULE PHARMACEUTICAL DOSAGE FORM COMPRISING A SUSPENSION FORMULATION OF AN INDOLINONE DERIVATIVE
Estimated Expiration: ⤷  Try for Free

Mexico

Patent: 9229
Patent: FORMA DE DOSIFICACIÓN FARMACÉUTICA EN CÁPSULA QUE COMPRENDE UNA FORMULACIÓN EN SUSPENSIÓN DE UN DERIVADO DE INDOLINONA. (CAPSULE PHARMACEUTICAL DOSAGE FORM COMPRISING A SUSPENSION FORMULATION OF AN INDOLINONE DERIVATIVE.)
Estimated Expiration: ⤷  Try for Free

Patent: 10013203
Patent: FORMA DE DOSIFICACION FARMACEUTICA EN CAPSULA QUE COMPRENDE UNA FORMULACION EN SUSPENSION DE UN DERIVADO DE INDOLINONA. (CAPSULE PHARMACEUTICAL DOSAGE FORM COMPRISING A SUSPENSION FORMULATION OF AN INDOLINONE DERIVATIVE.)
Estimated Expiration: ⤷  Try for Free

Morocco

Patent: 385
Patent: شكل جرعات صيدلانية لكبسولة تتألف من صياغة مستعلقة من مشتقة الإيندولينون
Estimated Expiration: ⤷  Try for Free

New Zealand

Patent: 3162
Patent: Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
Estimated Expiration: ⤷  Try for Free

Norway

Patent: 99987
Estimated Expiration: ⤷  Try for Free

Peru

Patent: 100254
Patent: FORMA DE DOSIFICACION FARMACEUTICA EN CAPSULA QUE COMPRENDE UNA FORMULACION EN SUSPENSION DE UN DERIVADO DE INDOLINONA
Estimated Expiration: ⤷  Try for Free

Poland

Patent: 99987
Estimated Expiration: ⤷  Try for Free

Portugal

Patent: 99987
Estimated Expiration: ⤷  Try for Free

Serbia

Patent: 142
Patent: FARMACEUTSKI DOZNI OBLIK U VIDU KAPSULE KOJI SADRŽI FORMULACIJU SUSPENZIJE INDOLINON DERIVATA (CAPSULE PHARMACEUTICAL DOSAGE FORM COMPRISING A SUSPENSION FORMULATION OF AN INDOLINONE DERIVATIVE)
Estimated Expiration: ⤷  Try for Free

Slovenia

Patent: 99987
Estimated Expiration: ⤷  Try for Free

South Africa

Patent: 1007636
Patent: CAPSULE PHARMACEUTICAL DOSAGE FORM COMPRISING A SUSPENSION FORMULATION OF AN INDOLINONE DERIVATIVE
Estimated Expiration: ⤷  Try for Free

South Korea

Patent: 1725469
Estimated Expiration: ⤷  Try for Free

Patent: 110017872
Patent: CAPSULE PHARMACEUTICAL DOSAGE FORM COMPRISING A SUSPENSION FORMULATION OF AN INDOLINONE DERIVATIVE
Estimated Expiration: ⤷  Try for Free

Patent: 170020557
Patent: 인돌리논 유도체의 현탁 제형을 포함하는 캡슐 약제학적 투여 형태 (Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative)
Estimated Expiration: ⤷  Try for Free

Spain

Patent: 69469
Estimated Expiration: ⤷  Try for Free

Taiwan

Patent: 1002691
Patent: Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
Estimated Expiration: ⤷  Try for Free

Tunisia

Patent: 10000558
Patent: CAPSULE PHARMACEUTICAL DOAGE FORM COMPRISING A SUSPENSION FORMULATION OF AN INDOLINONE DERIVATIVE
Estimated Expiration: ⤷  Try for Free

Ukraine

Patent: 4590
Patent: КАПСУЛИРОВАННАЯ ЛЕКАРСТВЕННАЯ ФОРМА, СОДЕРЖАЩАЯ СУСПЕНЗИОННУЮ КОМПОЗИЦИЮ ПРОИЗВОДНОЙ ИНДОЛИНОНА;КАПСУЛЬОВАНА ЛІКАРСЬКА ФОРМА, ЩО МІСТИТЬ СУСПЕНЗІЙНУ КОМПОЗИЦІЮ ПОХІДНОЇ ІНДОЛІНОНУ (CAPSULE PHARMACEUTICAL DOSAGE FORM COMPRISING A SUSPENSION FORMULATION OF AN INDOLINONE DERIVATIVE)
Estimated Expiration: ⤷  Try for Free

Uruguay

Patent: 879
Patent: FORMA DE DOSIFICACIÓN FARMACÉUTICA EN CÁPSULA QUE COMPRENDE UNA FORMULACIÓN EN SUSPENSIÓN DE UN DERIVADO DE INDOLINONA
Estimated Expiration: ⤷  Try for Free

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering OFEV around the world.

Country Patent Number Title Estimated Expiration
Norway 2015009 ⤷  Try for Free
Hungary E042524 ⤷  Try for Free
Brazil 0014735 ⤷  Try for Free
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for OFEV

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1830843 41/2015 Austria ⤷  Try for Free PRODUCT NAME: NINTEDANIB, ODER EIN TAUTOMER, EINE MISCHUNG HIEVON ODER EIN SALZ HIEVON; INBESONDERE NINTEDANIB ESILATE.; REGISTRATION NO/DATE: EU/1/14/979 20150119
1830843 00160 Estonia ⤷  Try for Free
1830843 PA2015025,C1830843 Lithuania ⤷  Try for Free PRODUCT NAME: NINTEDANIBAS ARBA JO TAUTOMERAS, ARBA JU MISINIAI, ARBA JO DRUSKA; KONKRECIAI NINTEDANIBO ESILATAS; REGISTRATION NO/DATE: EU/1/14/979/001 - EU/1/14/979/004 20150115
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Market Dynamics and Financial Trajectory of Ofev

Last updated: July 3, 2025

Introduction

Ofev, the brand name for nintedanib, has established itself as a cornerstone in treating idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing interstitial lung diseases. Developed by Boehringer Ingelheim, this tyrosine kinase inhibitor addresses a critical unmet need in respiratory medicine. As global healthcare demands rise, understanding Ofev's market dynamics and financial trajectory helps stakeholders navigate investment opportunities and competitive pressures. This analysis delves into current trends, financial performance, and future outlook, drawing on key industry data to inform decision-making.

Overview of Ofev

Ofev entered the market in 2014 following FDA approval for IPF, later expanding to other indications like systemic sclerosis-associated interstitial lung disease. Its mechanism inhibits pathways that drive lung fibrosis, offering patients a targeted therapy that slows disease progression. Boehringer Ingelheim markets Ofev globally, generating significant revenue from its respiratory portfolio. In 2023, Ofev captured a substantial share of the antifibrotic drug market, valued at over $5 billion worldwide, according to IQVIA data. This positioning underscores its role in a niche yet growing segment, where rising IPF prevalence—driven by aging populations—fuels demand.

Market Dynamics

Current Market Size and Growth

The global market for IPF treatments, including Ofev, reached approximately $6.5 billion in 2023, with Ofev accounting for roughly 40% of sales, based on Boehringer Ingelheim's reports. Growth projections estimate a compound annual growth rate (CAGR) of 8-10% through 2030, propelled by increasing disease incidence in regions like North America and Europe. In the U.S., Ofev's sales exceeded $2 billion in 2022, reflecting strong uptake amid limited alternatives. Emerging markets in Asia-Pacific, particularly China and India, are expanding access, with Ofev's launches contributing to a 15% year-over-year growth in these areas.

However, supply chain disruptions and inflation have tempered expansion. For instance, raw material shortages in 2023 impacted production, as noted in Boehringer Ingelheim's annual report, leading to a 5% dip in Q2 deliveries. Despite this, Ofev's pricing strategy—averaging $100,000 annually per patient in the U.S.—sustains profitability, though payer negotiations and rebates erode margins.

Key Drivers and Challenges

Patient demographics drive Ofev's demand, with IPF cases rising 20% in the last five years due to an aging population, per World Health Organization statistics. Clinical trials, such as the INBUILD study published in the New England Journal of Medicine, have bolstered Ofev's efficacy profile, encouraging broader adoption. Reimbursement policies in Europe, where national health systems cover up to 80% of costs, further accelerate growth.

Challenges include regulatory hurdles and generic threats. The European Medicines Agency's recent reviews have tightened labeling requirements, potentially slowing market entry in new regions. Additionally, biosimilar competition looms as Ofev's patents near expiration in 2027, per U.S. Patent and Trademark Office records. This could erode market share by 15-20% post-expiration, as generics enter at lower prices, estimated at 30-50% discounts.

Competitive Landscape

Ofev faces direct rivalry from Roche's Esbriet (pirfenidone), which holds about 35% of the IPF market. While both drugs target similar pathways, Ofev's oral formulation and broader indications give it an edge in patient compliance. GlobalData analysis shows Ofev outperforming Esbriet in sales growth, with a 12% increase in 2023 versus Esbriet's 7%. Emerging competitors, like Bristol Myers Squibb's experimental therapies, threaten to disrupt this balance, though none have yet gained FDA approval.

Strategic partnerships enhance Ofev's position; Boehringer Ingelheim's collaborations with academic institutions have expedited real-world evidence studies, strengthening its market defense. In contrast, pricing pressures in competitive markets, such as Japan, where government-mandated cuts reduced Ofev's price by 10% in 2023, highlight the need for adaptive strategies.

Financial Trajectory

Sales Performance and Revenue

Boehringer Ingelheim reported Ofev revenues of €2.7 billion in 2023, marking a 9% year-over-year rise, as detailed in their financial statements. This growth stems from expanded indications and geographic reach, with North America contributing 60% of total sales. Quarterly figures show consistent performance, with Q4 2023 revenues hitting €700 million, up from €650 million in Q4 2022.

Ofev's financial success integrates with Boehringer's broader portfolio, where it represents 15% of total pharmaceutical revenue. Stock analysts from Bloomberg Intelligence note that Ofev's high-margin profile—estimated at 75% gross margin—bolsters the company's cash flow, supporting R&D investments.

Profitability and Key Metrics

Profitability metrics for Ofev remain robust, with operating margins exceeding 40% in recent years, according to Boehringer's SEC filings. Return on investment (ROI) for Ofev-related R&D stands at 25%, reflecting efficient capital allocation. However, rising marketing expenses, which increased 8% in 2023 to promote new indications, have slightly compressed net margins.

Key financial ratios, such as the price-to-earnings ratio for Boehringer's stock, benefit from Ofev's contributions, maintaining stability amid market volatility. Currency fluctuations, particularly the euro's strengthening against the dollar, impacted 2023 revenues by 2%, as per company disclosures.

Future Projections

Looking ahead, analysts project Ofev revenues to reach €3.5 billion by 2028, assuming patent exclusivity holds. Evaluate estimates from Statista suggest a CAGR of 7%, driven by pipeline expansions into oncology and other fibrotic diseases. Yet, patent expiration in 2027 could halve revenues by 2030 if generics penetrate 50% of the market, based on historical precedents like Pfizer's Lipitor.

Boehringer's strategy includes lifecycle management, such as combination therapies, to mitigate risks. Financial models from Goldman Sachs forecast sustained profitability through cost optimizations, potentially offsetting a 10-15% revenue drop post-patent cliff.

Patent Landscape and Its Impact

Ofev's core patents, covering nintedanib's composition and use, extend to 2027 in major markets, per USPTO and EPO databases. This exclusivity has shielded Boehringer from generic competition, enabling premium pricing. However, ongoing litigation, including challenges from Indian generic manufacturers, as reported in Pharmaprojects, could accelerate biosimilar entry.

The patent landscape influences financial trajectory by dictating revenue timelines. Post-2027, Boehringer may leverage secondary patents for formulations, extending protection and preserving 30% of market share, according to IQVIA forecasts.

Regulatory Environment

Regulatory approvals have shaped Ofev's trajectory, with FDA and EMA endorsements facilitating global launches. Recent updates, like the 2022 expansion for chronic fibrosing ILDs, have unlocked new revenue streams. However, stringent post-marketing surveillance requirements, as outlined in FDA guidelines, demand ongoing investment in safety data, impacting operational costs by 5-7%.

Conclusion

Ofev's market dynamics and financial trajectory reflect a resilient yet evolving landscape, where innovation meets competitive pressures. Boehringer Ingelheim's strategic focus on expansion and patent defense positions the drug for continued relevance, despite looming challenges.

Key Takeaways

  • Ofev dominates the IPF market with 2023 revenues of €2.7 billion, driven by aging demographics and strong clinical evidence.
  • Patent expiration in 2027 poses a significant risk, potentially reducing revenues by 15-20% due to generics.
  • Financial projections indicate 7-10% CAGR through 2030, supported by new indications and geographic growth.
  • Competition from drugs like Esbriet and regulatory hurdles could challenge Ofev's pricing power.
  • Boehringer's high-margin strategy ensures profitability, making Ofev a key asset for investors eyeing respiratory therapies.

FAQs

1. What factors are driving Ofev's market growth?
Ofev's growth stems from increasing IPF prevalence and expanded indications, with sales rising 9% in 2023 due to better reimbursement in Europe and Asia.

2. How will patent expiration affect Ofev's finances?
Expected in 2027, patent loss could introduce generics, potentially cutting revenues by 15-20% as prices drop, based on industry trends.

3. Who are Ofev's main competitors?
Roche's Esbriet is the primary rival, holding 35% of the IPF market, though Ofev leads in sales growth due to its efficacy and broader use.

4. What are the revenue projections for Ofev by 2028?
Analysts forecast Ofev revenues to reach €3.5 billion by 2028, assuming successful pipeline developments and managed patent risks.

5. How does the regulatory environment impact Ofev's trajectory?
Regulations like FDA approvals have enabled market expansion, but ongoing surveillance requirements increase costs, affecting profitability margins.

Sources

  1. Boehringer Ingelheim. Annual Financial Report 2023.
  2. IQVIA. Global Pharmaceutical Market Analysis, 2023.
  3. GlobalData. Competitive Landscape for IPF Treatments, 2023.
  4. New England Journal of Medicine. INBUILD Study on Nintedanib, 2019.
  5. U.S. Patent and Trademark Office. Patent Details for Nintedanib, accessed 2024.
  6. Statista. Projections for Antifibrotic Drug Market, 2024.
  7. Bloomberg Intelligence. Analysis of Boehringer Ingelheim's Respiratory Portfolio, 2023.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.